Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

- Lilly submitted request for emergency use authorization (EUA) for monotherapy to U.S. Food and Drug Administration (FDA)   - New data show combination therapy met primary and secondary endpoints, reducing viral load, symptoms and hospitalizations; EUA request to follow   - Plan to initiate a